307 related articles for article (PubMed ID: 30924052)
1. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry.
Ge Z; Baber U; Claessen BE; Chandrasekhar J; Chandiramani R; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
J Thromb Thrombolysis; 2019 Jul; 48(1):42-51. PubMed ID: 30924052
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
[TBL] [Abstract][Full Text] [Related]
3. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
4. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
5. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R
Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067
[TBL] [Abstract][Full Text] [Related]
6. Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial.
Yan AT; Roe MT; Neely M; Cyr DD; White H; Fox KAA; Prabhakaran D; Armstrong PW; Ohman EM; Goodman SG
Coron Artery Dis; 2018 Sep; 29(6):469-476. PubMed ID: 29652672
[TBL] [Abstract][Full Text] [Related]
7. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED
Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
[TBL] [Abstract][Full Text] [Related]
9. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
10. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
Faggioni M; Baber U; Chandrasekhar J; Sartori S; Weintraub W; Rao SV; Vogel B; Claessen B; Kini A; Effron M; Ge Z; Keller S; Strauss C; Snyder C; Toma C; Weiss S; Aquino M; Baker B; Defranco A; Bansilal S; Muhlestein B; Kapadia S; Pocock S; Poddar KL; Henry TD; Mehran R
Catheter Cardiovasc Interv; 2019 Jul; 94(1):53-60. PubMed ID: 30656812
[TBL] [Abstract][Full Text] [Related]
11. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
12. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study.
Chandrasekhar J; Baber U; Sartori S; Aquino M; Moalem K; Kini AS; Rao SV; Weintraub W; Henry TD; Vogel B; Ge Z; Muhlestein JB; Weiss S; Strauss C; Toma C; DeFranco A; Claessen BE; Keller S; Baker BA; Effron MB; Pocock S; Dangas G; Kapadia S; Mehran R
Clin Res Cardiol; 2020 Jun; 109(6):725-734. PubMed ID: 31915997
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Godtfredsen SJ; Kragholm KH; Leutscher P; Jørgensen SH; Christensen MK; Butt JH; Gislason G; Køber L; Fosbøl EL; Sessa M; Bhatt DL; Torp-Pedersen C; Pareek M
Eur Heart J Acute Cardiovasc Care; 2022 Sep; 11(9):697-705. PubMed ID: 35950769
[TBL] [Abstract][Full Text] [Related]
15. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
16. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW
Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
De Servi S; Goedicke J; Schirmer A; Widimsky P
Eur Heart J Acute Cardiovasc Care; 2014 Dec; 3(4):363-72. PubMed ID: 24818952
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
19. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
[TBL] [Abstract][Full Text] [Related]
20. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
Chandrasekhar J; Baber U; Sartori S; Faggioni M; Aquino M; Kini A; Weintraub W; Rao S; Kapadia S; Weiss S; Strauss C; Toma C; Muhlestein B; DeFranco A; Effron M; Keller S; Baker B; Pocock S; Henry T; Mehran R
Catheter Cardiovasc Interv; 2017 Mar; 89(4):629-637. PubMed ID: 27152497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
